ReViral - About the company
ReViral is an acqui-hired company based in London (United Kingdom), founded in 2011 by Khattereh Ahmadi. It operates as a Developer of antiviral compounds for RSV. ReViral has raised $176M in funding from New Leaf Venture Partners and Novo Holdings. The company has 63 active competitors, including 17 funded and 5 that have exited. Its top competitors include companies like Precigen, Pulmocide and Relief Therapeutics.
Company Details
Developer of antiviral compounds for RSV. The company is developing its lead candidate RV521 as an antiviral therapy for Respiratory Syncytial Virus (RSV), which is an infection that often leads to asthma, COPD, and/or pneumonia.
- Website
- reviral.co.uk
- Social
- Email ID
- *****@reviral.co.uk
- Registered Address
- 2530 Meridian Parkway 2nd Floor Durham North Carolina
Key Metrics
Founded Year
2011
Location
London, United Kingdom
Stage
Acqui-Hired
Total Funding
$176M in 5 rounds
Latest Funding Round
Investors
Ranked
16th among 63 active competitors
Annual Revenue
£7.76M as on Apr 30, 2021
Employee Count
4 as on Apr 30, 2026
Legal entities associated with ReViral
ReViral is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
REVIRAL INC CIN: 7357943 , United States, Active | Dec 31, 2010 | - | 27 (As on Dec 31, 2020) | - |
Reviral Limited CIN: 7486063 , Germany, Active | Jan 09, 2011 | $10.2M (As on Apr 30, 2021) | 28 (As on Dec 31, 2021) |
Sign up to download ReViral's company profile
ReViral's funding and investors
ReViral has raised a total funding of $176M over 5 rounds. Its first funding round was on Dec 02, 2014. Its latest funding round was a Series C round on Aug 25, 2020 for $*****. 7 investors participated in its latest round. ReViral has 8 institutional investors.
Here is the list of recent funding rounds of ReViral:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 25, 2020 | 9157020 | Series C | 5556635 | 4805652 | 2008042 | 6344940 |
Aug 01, 2018 | 2495543 | Series B | 3518660 | 8102014 | 1771983 | |
Jul 2018 | 6541150 | Series B | 4862356 | 3519191 |
Access funding benchmarks and valuations. Sign up today!View details of ReViral's funding rounds and investors
ReViral's founders and board of directors
Founder? Claim ProfileThe founders of ReViral is Khattereh Ahmadi.
Here are the details of ReViral's key team members:
- Khattereh Ahmadi: Co-Founder of ReViral and founder of 1 other company. They serve on the board of 1 company.
ReViral's Board of Directors
ReViral's board has 10 active members. Ron Hunt, Lawrence M Blatt, Yi Zhou, Chau Khuong, Iain Dukes, Nanna Lüneborg, Raphael Wisniewski, Alex Sapir, Richard Ken and Kenneth Palmero are independent board members.Here is the list of ReViral's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
dtpeoyw | Team | - | Past | 4y 9m |
hvvkadt | Team | - | Past | 1y 7m |
llivpwe | Team | - | Past | 9y 5m |
Independent board member | - | Current | 6y 4m | |
uouozdr | Independent board member | - | Current | 1y 5m |
ugfkjmd | Independent board member | - | Current | 8y 5m |
sbybmka | Independent board member | - | Current | 5y 5m |
aupdoyi | Independent board member | - | Current | 7y 1m |
rpjtdxa | Independent board member | - | Current | 9y 5m |
jlhfbpy | Independent board member | - | Current | 8y 5m |
rbyjzlz | Independent board member | - | Current | 7y 8m |
nzrcmqq | Independent board member | - | Current | 4y 7m |
blqaykx | Independent board member | - | Current | 4y 3m |
myy{xuy | Independent board member | - | Past | 6y 2m |
lnmyawt | Independent board member | - | Past | 3y 1m |
jicuksv | Independent board member | - | Past | 8y 7m |
uwmxitr | Independent board member | - | Past | 6y 6m |
zmasyld | Independent board member | - | Past | 1y 2m |
kkblfhg | Independent board member | - | Past | 3y 3m |
View details of ReViral's Founder profiles and Board Members
ReViral's employee count trend
ReViral has 4 employees as of Apr 26. Here is ReViral's employee count trend over the years:
Uncover ReViral's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ReViral's Competitors and alternates
Top competitors of ReViral include Precigen, Pulmocide and Relief Therapeutics. Here is the list of Top 10 competitors of ReViral, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Precigen 1998, Germantown (United States), Public | Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases | $234M | 65/100 | |
2nd | Pulmocide 2013, London (United Kingdom), Series C | Developer of inhaled antifungal medicines for treating respiratory lung infections | $205M | 56/100 | |
3rd |  Relief Therapeutics 2013, Geneva (Switzerland), Public | Developer of drugs for treating pulmonary and infectious diseases | $2.75M | 56/100 | |
4th | Genome & Company 2015, Seongnam-si (South Korea), Public | Developer of microbiome-based immuno-oncology drugs | - | 55/100 | |
5th | Provider of gut microbiome data insights, analytics, tests, and therapeutics | $10.5M | 53/100 | ||
6th | _1572930198030.png?devicePixelRatio=2&height=30&width=30){kind=logo} Pneumagen 2016, St Andrews (United Kingdom), Series A | Developer of a treatment for viral respiratory tract infections and cancer | $18.3M | 53/100 | |
7th | Phylagen 2014, San Francisco (United States), Deadpooled | Provider of genome sequencing technology for microbial analysis | $14M | 47/100 | |
8th | Chengdu Kanghua Biological Products 2004, Chengdu (China), Unfunded | Developer of vaccines for respiratory disease and rabies infection | - | - | 45/100 |
9th | Siolta Therapeutics 2016, San Francisco (United States), Series C | Provider of microbiome therapeutics for treating multiple diseases | $42M | 43/100 | |
10th | Pulmotect 2007, Houston (United States), Series B | Developer of therapeutics against lung infections | $25.1M | 42/100 | |
16th | ReViral 2011, London (United Kingdom), Acqui-Hired | Developer of antiviral compounds for RSV | $176M | 36/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ReViral's competitors? Click here to see the top ones
ReViral's Investments and acquisitions
ReViral has made no investments or acquisitions yet.
News related to ReViral
Filter this list•
•
•
Pfizer offers $525 million for UK therapeutics companyBusiness Weekly newspaper•Apr 13, 2022•Pfizer, ReViral
•
LianBio’s Partner ReViral Enters into Acquisition Agreement with PfizerGlobeNewswire•Apr 07, 2022•ReViral, Pfizer, LianBio, Andera Partners
•
•
ReViral Raises $44 Million in Series C FinancingBusiness Wire•Aug 25, 2020•Brace Pharma Capital, Andera Partners, , Perceptive Advisors and 7 others
•
ReViral secures FDA fast track status for sisunatovir to treat severe RSV infectionPharmaceutical Business Review•Aug 05, 2020•ReViral
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ReViral
Explore our recently published companies
- Spec Services - Farmers Branch based, Unfunded company
- Performancelandex - Ridgefield based, 1978 founded, Unfunded company
- Mcrae Enterprises - Sellersburg based, 2006 founded, Unfunded company
- Echocanyonconsulting - Unfunded company
- Erbedesign - Unfunded company
- Serenusjohnson - Unfunded company
